A schoolchild's vaccination choice creates a strong enough externality that the state can mandate the shot once it is available.

The externality was real, but the pediatric-benefit, approval-timing, and implementation questions were much less clear than Jason treated them. Adult workplace mandates proved easier to defend and sustain than child school-entry mandates.

The cleanest way to get rid of masks and school disruption was to require pediatric vaccination rather than leave it to families.

That aged poorly. The mandate was delayed, the politics became toxic, and the state did not end up using this as its durable path out of school disruption.

The right line is to let private employers or venues require COVID vaccination while treating state-imposed school mandates for children much more skeptically.

That line held up better than the broader coercive approach. The private-institution model was imperfect but materially more durable than the announced state K-12 mandate.

By October 2021, the remaining case for forcing the last holdouts had weakened because voluntary adult access and therapeutic progress were expanding.

That is directionally right, especially once antivirals and better risk stratification entered the picture. The strongest later arguments were narrower and more context-specific than blanket coercion.

If society is willing to mandate vaccines in schools and workplaces, professional sports leagues should not be treated as a special exemption.

That is a coherent consistency point. The harder question was whether the underlying school mandate deserved to exist in the first place.

New treatments would reduce the long-run need for blunt social coercion by making COVID more clinically manageable.

That broadly held. Vaccines stayed important, but therapeutics and better risk management helped move the policy world away from the most maximal emergency logic.

Access inequality is the deeper problem here, not just the optics of one billionaire's giant account.

That is the strongest moral point in Chamath's case. A system that allows insiders to compound tax-advantaged private gains while ordinary savers are fenced out invites exactly this backlash.

The right answer is to let ordinary investors into early-stage private-company upside much more directly rather than mainly trying to punish past winners.

The access instinct is right, but the directness is not obviously right. The better version probably runs through pooled or diversified vehicles rather than retail concentration in single private names.

Retirement-account law should stop short of allowing multi-billion-dollar tax shelters built on founder-stage private deals.

That is a defensible policy line. A hard cap or similar boundary is easier to defend than pretending the original retirement rationale naturally covers accounts of this scale.

Once the spirit is violated, aggressive forced-distribution mechanics are an acceptable fix.

That overreaches. It is possible to cap future tax advantage without forcing illiquid assets out under punitive tax treatment.

A cap on giant tax-advantaged retirement balances is defensible, but forcing illiquid assets out under ordinary-income treatment is a worse and more distortive fix.

That is the strongest policy synthesis in the segment. It distinguishes between limiting future tax preference and imposing a needlessly punitive unwind.

Retirement accounts should have some path to alternative-asset exposure rather than being fenced away from early-stage upside entirely.

That concern is valid. The harder design question is how to provide the exposure without turning retirement saving into a reckless single-name casino.

If society socializes downside through retirement and health backstops, it should be cautious about encouraging concentrated speculative retirement bets.

That is a sound institutional point. A retirement system cannot be both a public safety net and an invitation to unlimited private lottery-ticket concentration without tension.

The best way to broaden access is through diversified or pooled exposure rather than direct do-it-yourself private-company speculation.

That is the cleanest middle ground between elite gatekeeping and reckless retail exposure.

The unicorn boom was fundamentally about real industrial replacement rather than pure financial theater.

That held up better than the bubble caricature. Many valuations proved too loose, but the broader shift toward software-driven and biology-driven industry replacement was real.

Corporate taxation is a better way to socialize the upside from winner-take-most modern companies than suppressing startup formation or relying only on personal tax hikes.

That is a serious and still compelling policy instinct. It does not solve every incentive problem, but it is more coherent than trying to kill the company-formation engine to fix distribution.

The prosperity created by the venture boom was broadly available to anyone with a good idea and therefore did not pose a deep distributional problem on its own.

The upside was real, but access was still highly unequal across geography, networks, capital pools, and skills. Sacks understates that bottleneck badly.

The main threat to the boom was government overspending and taxation rather than private-market fragility or later valuation compression.

Policy mattered, but the later correction showed the market had its own fragilities. The stronger version of Sacks's claim is that both forces mattered, not that government was the only storm cloud.

Over a multi-decade horizon, a broad index of frontier private companies could outperform the legacy public market they are displacing.

The thesis is plausible and still partly unresolved. Friedberg is directionally right about industrial turnover, but the exact scale of outperformance remains a long-range claim, not a settled fact.

The transition from old-economy firms to new-economy winners creates real disruption even if the long-run value creation is positive.

That is exactly the missing realism in a lot of venture triumphalism. The replacement story can be true and still impose serious short-run pain.